DC
RCUS icon

Decheng Capital’s Arcus Biosciences RCUS Stock Holding History

Decheng Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3M Sell
477,819
-63,740
-12% -$1.38M 1.56% 8
2025
Q4 		$12.9M Sell
541,559
-6,050
-1% -$123K 1.74% 8
2025
Q3 		$7.45M Buy
547,609
+387,609
+242% +$4.03M 1.3% 11
2025
Q2 		$811K Sell
160,000
-648,789
-80% -$5.54M 0.2% 19
2025
Q1 		$6.35M Hold
808,789
– – 1.78% 12
2024
Q4 		$12M Sell
808,789
-61,001
-7% -$996K 2.58% 6
2024
Q3 		$13.3M Hold
869,790
– – 3.15% 4
2024
Q2 		$13.2M Hold
869,790
– – 4.06% 3
2024
Q1 		$16.4M Hold
869,790
– – 2.2% 6
2023
Q4 		$16.6M Buy
+869,790
New +$13.9M 4.64% 6

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Decheng Capital's RCUS Position: Q1 2026 in Review

Decheng Capital reduced its Arcus Biosciences (RCUS) stake by 12% in Q1 2026, selling an estimated $1.38M and leaving 477,819 shares worth $10.3M. The position accounts for 1.56% of the portfolio, ranked #8.

Decheng Capital first reported a position in RCUS in Q4 2023 and has held it in 10 quarters since. The position peaked at $16.6M in Q4 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Decheng Capital held 477,819 shares of Arcus Biosciences worth $10.3M as of Q1 2026.
  • Decheng Capital sold 63,740 Arcus Biosciences shares in Q1 2026, an estimated $1.38M.
  • Arcus Biosciences made up 1.56% of Decheng Capital's portfolio in Q1 2026, its #8 holding.
  • Decheng Capital first reported a position in Arcus Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Decheng Capital's Arcus Biosciences position peaked at $16.6M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.